- Nachrichtendetail
-
01.04.2024 14:15:09 - dpa-AFX: *VERTEX ADVANCES INAXAPLIN INTO PHASE 3 PORTION OF PHASE 2/3 TRIAL FOR TREATMENT OF APOL1-MEDIATED KIDNEY DISEASE
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Vertex Pharmaceuticals | 882807 | NASDAQ | 475,665 | 04.06.24 20:41:25 | +5,485 | +1,17% | 475,500 | 475,830 | 472,570 | 470,180 |
